Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.
Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes derived from the tumor-bearing patient. A gene has been identified that directs the expression of antigen MZ2-E on a human melanoma cell line. This gene, which has been named MAGE-1, shows no similarity to known sequences and belongs to a family of at least 3 closely related genes. Gene MAGE-1 is expressed in approximately 40% of melanoma tumor samples and by some tumors of other histological types. No expression has been observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1, a HLA type found in approximately 25% of the population. Thus, precisely targeted experimental immunotherapy directed against antigen MZ2-E could be provided to individuals identified as HLA-A1 and MAGE-1 positive by HLA typing and analysis of the RNA of a small tumor sample.
Brussels Branch, Ludwig Institute for Cancer Research, Belgium.
M
M
Marchand
F
F
Brasseur
P
P
van der Bruggen
P
P
Coulie
T
T
Boon
D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D015870:Gene Expression; D015788:HLA-A1 Antigen / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008545:Melanoma / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014162:Transfection
D000951:Antigens, Neoplasm; D015788:HLA-A1 Antigen; C072011:MAGEA1 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins